Acta Oncologica最新文献_第8页

Aggressive end-of-life care in patients with gastrointestinal cancers - a nationwide study from Denmark. 胃肠道癌症患者的积极临终关怀--一项来自丹麦的全国性研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.41008

Stine Gerhardt, Kirstine Skov Benthien, Suzanne Herling, Marie Villumsen, Peter-Martin Karup

{"title":"Aggressive end-of-life care in patients with gastrointestinal cancers - a nationwide study from Denmark.","authors":"Stine Gerhardt, Kirstine Skov Benthien, Suzanne Herling, Marie Villumsen, Peter-Martin Karup","doi":"10.2340/1651-226X.2024.41008","DOIUrl":"10.2340/1651-226X.2024.41008","url":null,"abstract":"Background: Knowledge of determinants of aggressive end-of-life care is crucial to organizing effective palliative care for patients with gastrointestinal (GI) cancer.Purpose: This study aims to investigate the determinants of aggressive end-of-life care in patients with GI cancer.Methods: A national register-based cohort study using data from the Danish Register on Causes of Death, the Danish National Patient Register, and the Danish Palliative Database was the method of study employed.Participants/setting: All Danish patients who died from GI cancers from 2010 to 2020 comprised the study setting.Results: There were 43,969 patients with GI cancers in the cohort, of whom 62% were hospitalized in the last 30 days of life, 41% of patients died in the hospital, 10% had surgery, 39% were subjected to a radiological examination during the last 30 days of life and 3% had antineoplastic treatment during the last 14 days of life. Among all types of GI cancers, pancreatic cancer was significantly associated with all outcomes of aggressive end-of-life care except surgery. Patients in specialized palliative care (SPC) had lower odds of receiving aggressive end-of-life care and dying in the hospital. We found that patients with comorbidity and those who were divorced had higher odds of being hospitalized at the end of life and dying in the hospital.Interpretation: Aggressive end-of-life care is associated with disease factors and socio-demographics. The potential to reduce aggressive end-of-life care is considerable in patients with GI cancer, as demonstrated by the impact of SPC. However, we need to address the needs of patients with GI cancer who do not receive SPC.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"915-923"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proportion and characteristics of screen-detected and non-screen-detected colo-rectal cancers in Germany. 德国筛查出和未筛查出结肠直肠癌的比例和特征。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-24 DOI: 10.2340/1651-226X.2024.40234

Michel Hornschuch, Sarina Schwarz, Ulrike Haug

{"title":"Proportion and characteristics of screen-detected and non-screen-detected colo-rectal cancers in Germany.","authors":"Michel Hornschuch, Sarina Schwarz, Ulrike Haug","doi":"10.2340/1651-226X.2024.40234","DOIUrl":"10.2340/1651-226X.2024.40234","url":null,"abstract":"Background: Germany has a long-standing colorectal cancer (CRC) screening offer. We aimed to quantify and characterize screen-detected colorectal cancers (sdCRCs) in Germany.Methods: We conducted a cross-sectional study based on a healthcare database covering ~20% of the German population; we included CRC patients aged ≥ 55 years diagnosed in 2010-2018. Patients with a screening colonoscopy or a fecal occult blood test followed by colonoscopy within 180 days before diagnosis were classified as sdCRCs and compared to non-sdCRCs regarding age, stage and comorbidities.Results: In 2018, 25% of male and 22% of female CRC patients were screen-detected. Regarding characteristics of all included CRC cases (N = 82,538), sdCRC patients were younger than non-sdCRCs (average difference men / women: 2.6 / 4.4 years). The proportion of advanced CRC among sdCRCs and non-sdCRCs, respectively, was 33 and 42% in women (men: 36 and 45%). Severe comorbidities were more prevalent in non-sdCRCs compared to sdCRCs (e.g. in male / female patients aged 65-74: 35% vs. 27% / 26% vs. 19%). Prevalences of hypertension and obesity were similar in both groups.Interpretation: Our study suggests that about one fourth of CRCs in Germany are screen-detected. Among patients with non-sdCRC, not only advanced stage but also severe comorbidity was more common than in sdCRCs.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"924-931"},"PeriodicalIF":2.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142708532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study. 弥漫性胶质瘤成年患者的静脉血栓栓塞风险：一项基于全国人口的研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-14 DOI: 10.2340/1651-226X.2024.40137

Frederik R Hovman, Frantz R Poulsen, Steinbjørn Hansen, Rikke H Dahlrot

{"title":"The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study.","authors":"Frederik R Hovman, Frantz R Poulsen, Steinbjørn Hansen, Rikke H Dahlrot","doi":"10.2340/1651-226X.2024.40137","DOIUrl":"10.2340/1651-226X.2024.40137","url":null,"abstract":"Background and purpose: Venous thromboembolism (VTE) is a cause of increased morbidity and risk of death. Studies report VTE in up to 30% of glioma patients but the results vary. The VTE risk is relevant when evaluating prophylaxis to avoid unnecessary bleeding or overdiagnosis. This study examines the VTE incidence in patients with glioma WHO grade 2-4, and when VTE occurred, risk factors, and overall survival (OS) for patients with WHO grade 4.Materials and methods: In total 3,630 patients with WHO grade 2 (n = 230), grade 3 (n = 317), and grade 4 (n = 3,083) gliomas from 2010 to 2018 were identified using the Danish Neuro-Oncology Registry. VTE diagnoses and time of death were obtained from Statistics Denmark.Results and interpretation: The VTE incidence was 5.2, 6.3, and 6.8% in patients with WHO grade 2, 3, and 4 gliomas, respectively. The VTE incidence rate was highest during the first 3 months after the diagnosis with 53 events. Increasing age (HR 1.03, 95%CI 1.01-1.04), male sex (HR 1.47, 95%CI 1.09-1.99), poor performance status (HR 1.57, 95%CI 1.10-2.25), and post-operative long-course radiochemotherapy (HR 2.10, 95%CI 1.19-3.72) were predictors of VTE in patients with glioma WHO grade 4. There was no difference in OS comparing patients having VTE to those without (p = 0.068). In conclusion, patients with glioma WHO grade 2-4 were at high risk of VTE, especially the first 3 months after diagnosis. Increasing age, male sex, poor performance status, and long-course radiochemotherapy were associated with increased risk of VTE in patients with glioma WHO grade 4.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"887-892"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient reported experiences of health care, quality of life and preoperative information in colon cancer. 结肠癌患者报告的医疗保健经验、生活质量和术前信息。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-14 DOI: 10.2340/1651-226X.2024.40933

Maria Reinwalds, Charlotta Larsson, Rode Grönkvist, Eva Angenete

{"title":"Patient reported experiences of health care, quality of life and preoperative information in colon cancer.","authors":"Maria Reinwalds, Charlotta Larsson, Rode Grönkvist, Eva Angenete","doi":"10.2340/1651-226X.2024.40933","DOIUrl":"10.2340/1651-226X.2024.40933","url":null,"abstract":"Background and purpose: Cancer may create problems and needs associated with impaired quality of life (QoL). The first health care encounter is important to enable patients to cope and may ultimately impact QoL. The aim of this study was to describe the patients' experiences of encounters with health care professionals. Another aim was to explore the possible impact that the encounters may have on QoL 1 year after a colon cancer diagnosis. We also wanted to investigate whether patients had received information about treatment related side-effects.Patients and methods: This substudy within the QoLiCOL (Quality of Life in COLon cancer) study included 1687 patients (male n = 876, female n = 811, mean age 71) between 2015 and 2019. Questionnaires were answered at diagnosis and after 1 year. QoL was self-assessed with a seven-point Likert scale. Analyses were performed using descriptive statistics and ordinal logistic regression.Results: A total of 1,550 patients (91.9%) reported feeling well received by health care professionals. We found no statistically significant association with QoL. Patients (87%) reported feeling well informed about their treatment, but few patients recalled having received information regarding potential side effects on bowel or sexual function.Interpretation: Patients with colon cancer generally had a positive experience of the encounter with health care where they felt both well received and well informed. However, the amount of relevant information received was scarce. This indicates that it may be difficult to identify whether patients are properly informed prior to treatment for colon cancer only by asking if they feel well informed.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"893-900"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival outcomes for HER2-low breast cancer: Danish national data. HER2 低水平乳腺癌的生存结果：丹麦全国数据。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-14 DOI: 10.2340/1651-226X.2024.41280

Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm

{"title":"Survival outcomes for HER2-low breast cancer: Danish national data.","authors":"Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm","doi":"10.2340/1651-226X.2024.41280","DOIUrl":"10.2340/1651-226X.2024.41280","url":null,"abstract":"Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER2 IHC score of 0). HER2-low is defined as a score of 1+ or 2+ in an immunohistochemical (IHC) assay without HER2 gene amplification.Materials and methods: Patients with HER2 0 or HER2-low BC from the national Danish Breast Cancer Group database were examined by multivariable survival analysis in a retrospective noninterventional investigation. Patients were grouped as either HER2 0 or HER2-low. The primary endpoint was time to recurrence (TR), and the secondary endpoints were overall survival (OS) and distant recurrence-free interval (DRFI).Results: 41,610 patients were included (12,981 with HER2 0 BC and 28,629 with HER2-low BC). HER2-low BC was associated with a lower risk of recurrence (hazard ratio [HR]: 0.92, p = 0.03). Regarding secondary endpoints, HER2-low disease was linked to improved overall OS (HR: 0.94, p = 0.02). No statistically significant effect of HER2-low was found for DRFI, along with no differential effect of HER2-low according to estrogen receptor (ER) status.Interpretation: HER2-low BC was found to show an improved HR for OS and DRFI compared with HER2 0 BC; however, further studies are need to establish whether it represents a separate biological entity.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"878-886"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial. NIVO-TIL：针对未经治疗的转移性黑色素瘤的联合抗PD-1疗法和收养性T细胞转移：一项探索性开放标签I期试验。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-07 DOI: 10.2340/1651-226X.2024.40495

Jean-Matthieu L'Orphelin, Ugo Lancien, Jean-Michel Nguyen, Francisco J S Coronilla, Soraya Saiagh, Julie Cassecuel, Lise Boussemart, Anne Dompmartin, Brigitte Dréno

{"title":"NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial.","authors":"Jean-Matthieu L'Orphelin, Ugo Lancien, Jean-Michel Nguyen, Francisco J S Coronilla, Soraya Saiagh, Julie Cassecuel, Lise Boussemart, Anne Dompmartin, Brigitte Dréno","doi":"10.2340/1651-226X.2024.40495","DOIUrl":"10.2340/1651-226X.2024.40495","url":null,"abstract":"Background and purpose: In patients with metastatic melanoma who respond to anti-PD-1 therapy, the proliferation of intra-tumour CD8+ T cells is directly correlated with the clinical response, making tumour-infiltrating lymphocytes (TILs) a treatment of interest in combination with a PD-1 inhibitor, which is the undisputed gold standard in the management of metastatic melanoma. The aim of this trial was, therefore, to evaluate the safety and efficacy of sequential combination therapy consisting of nivolumab (a PD-1 inhibitor) and TILs adoptive T cells in patients with metastatic melanoma.Materials and methods: We performed an exploratory, prospective, single-centre, open-label, non-randomised, uncontrolled phase I/II study. We enrolled 10 previously untreated patients with advanced melanoma. The treatment regimen was neoadjuvant anti-PD-1 therapy followed by 2 injections of TILs and a second sequence of anti-PD-1 therapy.Results and interpretation: Among the four patients who received the autologous TILs + nivolumab combination, three (75%) achieved an objective response (two achieved a partial response [PR] at the end of the study, two achieved a complete response [CR]), and one achieved a CR at the end of the study. Among these three patients, one had a PR, and two had stable disease (SD) after the nivolumab course and before any TILs administration, reinforcing the importance of the tumour response after TILs injection. These responses were persistent, ranging from 9 months to 3.4 years.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"867-877"},"PeriodicalIF":2.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy. 年龄对接受确定性放疗的局部前列腺癌患者的临床病理特征和治疗效果的影响。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-05 DOI: 10.2340/1651-226X.2024.40759

Cem Onal, Ozan Cem Guler, Aysenur Elmali, Birhan Demirhan, Melek Yavuz

{"title":"The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy.","authors":"Cem Onal, Ozan Cem Guler, Aysenur Elmali, Birhan Demirhan, Melek Yavuz","doi":"10.2340/1651-226X.2024.40759","DOIUrl":"10.2340/1651-226X.2024.40759","url":null,"abstract":"Background: This study assessed the biochemical disease-free survival (bDFS), prostate cancer-specific survival (PCSS), overall survival (OS), and side effects in patients aged < 70 and ≥ 70 years following definitive radiotherapy (RT). It also analysed the correlation between age at diagnosis and clinicopathological characteristics of prostate cancer (PCa).Methods: The prognostic factors for bDFS, PCSS, and OS were determined through univariable and multivariable analyses. Two age groups were also compared in terms of acute and late grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicities, the predictors of which were determined through logistic regression analysis.Results: Of the 1,328 patients, 715 (53.8%) and 613 (46.2%) were aged < 70 and ≥ 70 years, respectively. Median follow-up time was 84.5 months. No significant differences in the 7-year bDFS (86.3% vs. 86.8%) and PCSS rates (92.9% vs. 93.3%) were found between the ≥ 70 and < 70 age groups. The multivariable analysis showed that advanced clinical T stage, high International Society of Urological Pathology (ISUP) grade, and high-risk disease independently predicted poor bDFS and PCSS. Metastatic lymph nodes were another bDFS prognostic factor. The multivariable analysis identified age ≥ 70 years, cardiac events at diagnosis, advanced stage, higher ISUP grade, and non-use of simultaneous integrated boost technique as negative factors for OS. Additionally, diabetes and transurethral resection of the prostate (TUR-P) independently predict late-grade ≥ 2 GU toxicity.Interpretation: Definitive RT is a safe and effective treatment for patients with localised PCa no matter their age. Although patients over 70 years have higher risk factors and comorbidities, their bDFS, PCSS, and toxicities were comparable to those of patients aged < 70 years.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"858-866"},"PeriodicalIF":2.7,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer incidence following non-neoplastic medical conditions: a prospective population-based cohort study. 非肿瘤性病症后的癌症发病率：一项基于人群的前瞻性队列研究。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-04 DOI: 10.2340/1651-226X.2024.40757

Lauri J Sipilä, Tomas Tanskanen, Sanna Heikkinen, Karri Seppä, Mervi Aavikko, Janne Ravantti, Lauri A Aaltonen, Janne Pitkäniemi

{"title":"Cancer incidence following non-neoplastic medical conditions: a prospective population-based cohort study.","authors":"Lauri J Sipilä, Tomas Tanskanen, Sanna Heikkinen, Karri Seppä, Mervi Aavikko, Janne Ravantti, Lauri A Aaltonen, Janne Pitkäniemi","doi":"10.2340/1651-226X.2024.40757","DOIUrl":"10.2340/1651-226X.2024.40757","url":null,"abstract":"Background and purpose: Many non-neoplastic diseases have been established to be tumorigenic, and cancers are sometimes misdiagnosed as non-neoplastic diseases. We conducted a comprehensive registry-based study of site-specific cancer diagnosis risk following the diagnosis of any preceding medical condition (PMC) encoded by the International Classification of Diseases (ICD)-10 classification.Material and methods: We analyzed healthcare data and cancer data for a random population-based sample of 2.5 million individuals living in Finland on January 1, 2000. Hazard ratios for each PMC and cancer pair were estimated using piecewise constant hazard regression models. P-values were corrected for multiple testing with the Bonferroni method.Results: Several lifestyle-related PMCs were associated with the risk of cancer diagnosis, exemplified by chronic obstructive pulmonary disease and subsequent lung cancer diagnosis risk (female hazard ratio [HR] = 9.91, 95% confidence interval [CI]: 9.18-19.7, p-adj. < 0.0001; male HR = 5.69, 95% CI: 5.43-5.96, p-adj. < 0.0001). Diagnosis risk of ill-defined cancers appeared to increase following diagnosis of Alzheimer's disease (AD). We identified rare PMCs of potential interest.Interpretation: A considerable proportion of the statistically significant associations were explainable by tobacco smoking and alcohol use. The enrichment of ill-defined cancer diagnoses in persons with AD, together with the overall inverse association between AD and cancer, may reflect underdiagnosis of cancer in this patient population. Our results provide a useful resource for research on the prevention and early detection of cancer.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"841-849"},"PeriodicalIF":2.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology and treatment outcome of nasopharyngeal carcinoma in a low-incidence population - a DAHANCA analysis in Denmark 2000-2018. 低发病率人群中鼻咽癌的流行病学和治疗效果--2000-2018 年丹麦 DAHANCA 分析。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-11-04 DOI: 10.2340/1651-226X.2024.40499

Erik Schiess, Kristian H Jensen, Morten H Kristensen, Jørgen Johansen, Jesper G Eriksen, Christian Maare, Maria Andersen, Mohammad Farhadi, Christian R Hansen, Jens Overgaard, Lisa L Hjalgrim, Giedrius Lelkaitis, Jeppe Friborg

{"title":"Epidemiology and treatment outcome of nasopharyngeal carcinoma in a low-incidence population - a DAHANCA analysis in Denmark 2000-2018.","authors":"Erik Schiess, Kristian H Jensen, Morten H Kristensen, Jørgen Johansen, Jesper G Eriksen, Christian Maare, Maria Andersen, Mohammad Farhadi, Christian R Hansen, Jens Overgaard, Lisa L Hjalgrim, Giedrius Lelkaitis, Jeppe Friborg","doi":"10.2340/1651-226X.2024.40499","DOIUrl":"10.2340/1651-226X.2024.40499","url":null,"abstract":"Introduction: Nasopharyngeal carcinoma (NPC) is a rare disease and most studies have therefore been conducted in endemic areas. The aim of this study was to describe epidemiology and treatment outcomes of NPC in a population-based, non-endemic setting.Material and methods: Patients with NPC diagnosed in Denmark from 2000 to 2018 were identified in the Danish Head and Neck Cancer Study Group (DAHANCA) database. Clinical records were reviewed to obtain missing data and confirm outcome, histological subtypes, Epstein-Barr virus (EBV)-status, prognostic factors, and treatment.Results: NPC was identified in 394 patients corresponding to age-standardized incidence rates of 0.5 and 0.2 per 100,000 in men and women, respectively. The 5-year overall (OS) and disease-specific survival (DSS) were 56 and 66%. In multivariate analysis, stage, smoking, and histology affected both OS and DSS, as patients with undifferentiated carcinomas had superior outcomes. Tumor EBV-status was determined in 221 patients, of whom 160 (72%) tested positive. EBV-positivity was associated with an improved OS in univariate analysis, but not after adjustment for relevant clinical factors.Interpretation: NPC is a rare malignancy in Denmark, and three in four patients have EBV-associated tumors. Tumor histology, smoking status, and stage, but not EBV-status, had independent prognostic impact on survival.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"850-857"},"PeriodicalIF":2.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coverage of mammography imaging in and outside an organized breast cancer screening program - variation by age and sociodemographic groups. 有组织的乳腺癌筛查计划内外的乳腺 X 射线成像覆盖率--因年龄和社会人口群体而异。

IF 2.7 3区医学

Acta Oncologica Pub Date : 2024-10-29 DOI: 10.2340/1651-226X.2024.40830

Joanna Fuhrmann, Sirpa Heinävaara, Tytti Sarkeala, Milla Lehtinen, Maiju Pankakoski

{"title":"Coverage of mammography imaging in and outside an organized breast cancer screening program - variation by age and sociodemographic groups.","authors":"Joanna Fuhrmann, Sirpa Heinävaara, Tytti Sarkeala, Milla Lehtinen, Maiju Pankakoski","doi":"10.2340/1651-226X.2024.40830","DOIUrl":"10.2340/1651-226X.2024.40830","url":null,"abstract":"Introduction: In recent decades, attendance to organized breast cancer screening has been decreasing in European countries. This could be partly due to an increase in the use of opportunistic screening. The aim of this study was to assess the coverage of imaging in and outside the screening program in Finland during the period of 1999-2018. We also compared the usage of imaging services across sociodemographic groups in the more recent years (2017-2018).Methods: Our initial data consisted of 1,159,000 screening-target-aged women (50-69 years) in 1999-2018 and 1,849,000 women aged 30-89 years in 2017-2018. Data on organized breast cancer screening program was drawn from the Finnish Cancer Registry and supplemented with comprehensive individual data on mammograms and ultrasounds performed outside the program.Results: Among the screening-aged women (50-69), a clear decline in the overall imaging coverage was observed during the study period (from 89 to 85%). The use of outside imaging increased slightly but not enough to compensate for the overall decrease. There were large differences in coverages between sociodemographic groups. Compared to manual workers and the unemployed, upper-level employees were around two times more active in using outside imaging (8.2% vs. 3.6% and 4.3%, respectively).Interpretation: Overall breast imaging coverage has slowly decreased during the 2000s, while outside imaging has increased slightly. The coverage of imaging in and outside the program largely followed the same trends, with the highest usage concentrating on higher socioeconomical groups, native speakers and highly educated women.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"833-840"},"PeriodicalIF":2.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0